- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Vanda Pharmaceuticals Inc (VNDA)Vanda Pharmaceuticals Inc stock price live, this page displays NASDAQ VNDA stock exchange data. View the VNDA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Vanda Pharmaceuticals Inc real time stock price chart below.
What Is the Vanda Pharmaceuticals Inc Stock Price Today?
The Vanda Pharmaceuticals Inc stock price today is 4.60.
What Is the Stock Symbol for Vanda Pharmaceuticals Inc?
The stock symbol for Vanda Pharmaceuticals Inc is "VNDA."
What Stock Exchange Does Vanda Pharmaceuticals Inc Trade On?
Vanda Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Vanda Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Vanda Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VNDA quote. (ISIN: US9216591084)
What Is the Vanda Pharmaceuticals Inc Stock Price Today?
The Vanda Pharmaceuticals Inc stock price today is 4.60.
What Is the Stock Symbol for Vanda Pharmaceuticals Inc?
The stock symbol for Vanda Pharmaceuticals Inc is "VNDA."
What Stock Exchange Does Vanda Pharmaceuticals Inc Trade On?
Vanda Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Vanda Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Vanda Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VNDA quote. (ISIN: US9216591084)
4.60
-0.22(-4.56%)
Closed
After Hours
4.74+0.14(+3.04%)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.55
4.84
52 wk Range
3.46
6.75
VNDA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual trading volume
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.554.84
52 wk Range
3.466.75
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
VNDA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Sell
Price Target
10.43
Upside
+126.74%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
Vanda Pharmaceuticals Inc Company Profile
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson’s disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company’s pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Vanda Pharmaceuticals Inc SWOT Analysis
Financial Surge | Vanda Pharmaceuticals reports impressive Q2 2024 results, with net product sales reaching $50.5 million, surpassing analyst estimates and showing significant growth. |
Product Portfolio Pivot | Explore Vanda's strategic expansion of Fanapt into bipolar disorder and the relaunch of PONVORY for multiple sclerosis, driving revenue growth and market reach. |
Commercial Expansion | Delve into Vanda's aggressive commercial strategy, including tripling its psychiatry-focused salesforce to 150 representatives, aimed at maximizing product value. |
Pipeline Potential | Analysts view tradipitant's potential approval for gastroparesis as a key growth driver, with a $13 price target from Cantor Fitzgerald reflecting optimism. |
VNDA Full Pro Research
Institutional-Grade Stock Analysis
Understand how VNDA earns money
Financial health at a glance
Bearish and bullish outlooks
Latest expert insights
Actionable Pro Tips, and many more...
Gain access to 1400+ in-depth research reports on the most popular US stocks
Vanda Pharmaceuticals Inc Earnings Call Summary for Q4/2024
- Q3 2024 revenues down 1% YoY to $145.6M; Hetlioz sales fell 28% due to generic competition
- PONVORY sales reached $21.3M post-acquisition; Fanapt sales slightly down at $67.6M for first 9 months
- Net loss of $14M for first 9 months of 2024; increased operating expenses from commercial launches
- 2024 guidance raised: total net product sales expected $190M-$210M; year-end cash projected $370M-$390M
- Preparing new drug applications for milsaperidone and PONVORY in additional indications
Last Updated: 08/11/2024, 07:20 am
Read Full TranscriptCompare VNDA to Peers and Sector
Metrics to compare | VNDA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVNDAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −17.1x | −3.7x | −0.6x | |
PEG Ratio | 0.07 | −0.04 | 0.00 | |
Price/Book | 0.5x | 0.8x | 2.6x | |
Price / LTM Sales | 1.5x | 2.4x | 3.2x | |
Upside (Analyst Target) | 91.9% | 45.8% | 46.2% | |
Fair Value Upside | Unlock | 2.0% | 7.0% | Unlock |
Analysts' Recommendations
3 Buy
1 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 10.43
(+126.68% Upside)
People Also Watch
FAQ
What Is the Vanda (VNDA) Stock Price Today?
The Vanda stock price today is 4.60
What Stock Exchange Does Vanda Trade On?
Vanda is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for Vanda?
The stock symbol for Vanda is "VNDA."
What Is the Vanda Market Cap?
As of today, Vanda market cap is 269.38M.
What is Vanda Earnings Per Share?
The Vanda EPS is -0.283.
What Is the Next Vanda Earnings Date?
Vanda will release its next earnings report on 04 Feb 2025.
From a Technical Analysis Perspective, Is VNDA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.